Efficacy of myo‐inositol and <scp>d</scp>‐chiro‐inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open‐label study

Kachhawa, Garima; Kumar, K. V. S. Hari; Kulshrestha, Vidushi; Khadgawat, Rajesh; Mahey, Reeta; Bhatla, Neerja

doi:10.1002/ijgo.13971

Cited by 8 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant reduction in the mean serum insulin levels demonstrated by the current study may suggest improved insulin sensitivity after treatment. Another study by Kachhawa et al evaluated the efficacy of MI-DCI, demontrated that MI-DCI is effective in regularizing menstrual cycles and improving insulin resistance [ 17 ]. This corroborated with a significant decrease in FPG, PPG, and insulin resistance index (HOMA IR) following treatment with MI-DCI.…”

Section: Discussionmentioning

confidence: 99%

Management of polycystic ovary syndrome among Indian women using myo‐inositol and D-chiro-inositol

Vyas¹

2022

Bioinformation

View full text Add to dashboard Cite

Myo-Inositol and D-chiro-inositol (MI-DCI) are used in the treatment of polycystic ovarian syndrome (PCOS) due to their insulin-sensitizing actions. Therefore, it is of interest to evaluate the treatment patterns, clinical effectiveness and safety of MI-DCI combination in management of PCOS in Indian women .Data from 50 healthcare centers across India between September 2019 and February 2020 were used in the study. Women aged 12-45 years diagnosed with PCOS, who had received MI-DCI (550-150 mg) were included. The outcome parameters were change in weight, luteinizing hormone (LH)/follicle stimulating hormone (FSH) ratio, hirsutism, blood glucose and insulin levels, HOMA-IR, and lipid profile. 283 women (mean age: 27.74 years; body mass index: 26.89 kg/m2); of which 197 (69.61%) reported reduction in weight after treatment with MI-DCI. The proportion of hirsutism score reduced after treatment, no hirsutism increased from 31.07% to 50.51% and the severe reduced from 4.85% to zero and moderate from 32.52% to 6.12%. There was a significant reduction in LH:FSH ratio (mean difference: 0.25 mg/dL; p=0.021), free testosterone (mean difference: 1.49; p<0.001) and dehydroepiandrosterone (mean difference: 21.49; P<0.001) levels after regular use of MI-DCI tablets.Treatment with MI-DCI resulted in significant improvement in insulin, HOMA score, FPG, PPG and lipid profile. The therapy restored menstruation and spontaneous ovulation and significantly attenuated the LH/FSH ratio. Thus, MI-DCI (550-150 mg) has shown multidimensional benefits in improving the hormonal, glycemic, and lipid profile of women with PCOS with considerable efficacy and tolerability.

show abstract

Section: Discussionmentioning

confidence: 99%

Management of polycystic ovary syndrome among Indian women using myo‐inositol and D-chiro-inositol

Vyas¹

2022

Bioinformation

View full text Add to dashboard Cite

show abstract

“…The main difference between these 2 is that myo-inositol helps with the activation of transporters and the use of glucose by the body, while d-chiroinositol participates in the synthesis and storage of glycogen (33). Some of the benefits that have been observed with the use of inositol are: o Regulation of the menstrual cycle: when patients were treated for 6 months with MI + ICD (550 + 150 mg, ratio 3.6:1) twice a day and CHC (ethinyl estradiol 20 µg + drospirenone 3 mg) once a day, it was observed a regulation in the cycles, which was maintained up to 3 months after finishing the treatment (34). o Reduce insulin resistance and lipid profile: intake of 2-4g myo-inositol for 12-24 weeks in women with polycystic ovary syndrome had beneficial effects on glycemic control, triglyceride and VLDL cholesterol levels and genetic expression of peroxisome proliferator (PPAR-γ) (35,36).…”

Section: Supplementationmentioning

confidence: 99%

Dietary Management in Polycystic Ovary Syndrome: Review

Paula Bernarda Toledo Caguana,

Jocelyne Karina Ordóñez Brito,

Juan Sebastián Marca Cabrera

et al. 2023

EPRA

View full text Add to dashboard Cite

Introduction: polycystic ovarian syndrome (PCOS) is an endocrine-gynecological disorder that affects and worsens the quality of life of women by altering their physiology and psychology in reproductive age. People with PCOS are more likely to develop insulin resistance, obesity, metabolic syndrome, systemic inflammation, or a combination of these chronic conditions. All of these conditions or diseases increase the risk of diabetes, cardiovascular disease, and other diseases. There are several methods to reduce the chances of suffering from these diseases, among which are proper dietary management, which is why this review has been developed, whose purpose is to gather the information available to date. Objective: describe actual and available dietary treatments for polycystic ovary syndrome (PCOS). Methodology: a total of 67 articles were analyzed in this review, including review and original articles, as well as clinical cases, of which 39 bibliographies were used because the other articles were not relevant for this study. The sources of information were PubMed, Scopus and Web of Science; the MeSH keywords Polycystic Ovary Syndrome Diet Treatment and DeCS Síndrome de ovario poliquístico Tratamiento Dieta were used. Conclusions: currently there are diets and supplements that have been rigorously investigated (through clinical trials) within which certain benefits have been observed with respect to body composition and biomarkers. Within these diets and supplements we find the following diets: ketogenic, mediterranean, low glycemic index, pulse-based, DASH and restricted feeding. At the moment, the number of studies, their magnitude and duration remain insufficient to guarantee reliable recommendations for patients, which is why it is essential that larger studies be carried out to guarantee adequate therapy for the benefit of patients. Keywords: Polycystic Ovary Syndrome. PCOS. Diet. Dietary Treatment. Treatment. Hyperandrogenism.

show abstract

“…За даними дослідження Montt-Guevara et al (2021), проведеного in vitro, DХІ відіграє безпосередню роль у диференціації та функціонуванні адипоцитів людини, він синергічно взаємодіє з інсуліном і естрогеном шляхом залучення шляхів сигнальної трансдукції, що беруть участь у накопиченні ліпідів та глюкози [27]. Інозитоли широко застосовуються в менеджменті метаболічних порушень при СПКЯ [11,15,16], чоловічої неплідності [10], показують позитивний ефект щодо запобігання розвитку гестаційного діабету в жінок з ожирінням [12,22].…”

Section: обговоренняunclassified

Optimization of surgical treatment of uterine myoma in women with obesity and the metabolic syndrome

Kosei,

Tatarchuk,

Plaksiieva

et al. 2023

View full text Add to dashboard Cite

Objectives: to evaluate the benefits of delayed conservative myomectomy with the aim of reducing body weight and correcting hematological and metabolic parameters against the background of the use of gonadotropin-releasing hormone (GnRH) agonists and a combination of myo-inositol and D-chiro-inositol (Inofolic combi) in obese patients with metabolic syndrome by comparing this technique with immediate surgery.Materials and methods. The study included 72 patients with uterine fibroids and obesity who required conservative myomectomy. Patients were offered to postpone surgical intervention in order to correct body weight, metabolic and hematological indicators. As a preoperative preparation, patients were recommended to use GnRH agonists (goserelin), inositols, and iron preparations for anemia. Patients were divided into 2 groups: the first group (n = 31) followed all these recommendations, the second group (n = 41) refused to follow the recommendations and postponed surgical treatment. Group 1 underwent surgical treatment 3 months after the start of treatment, group 2 – after the initial consultation.Results. Patients of the first group lost an average of 7.3 ± 1.4 kg of body weight during preoperative preparation, their hemoglobin level increased by an average of 21.78%, and the volume of the largest myomatous node decreased by an average of 21.82%. The duration of the operation was significantly shorter in group 1 (75 ± 3.84 min) than in group 2 (118 ± 5.33 min). Laparotomy in the first group was not performed in any patient, in the second group it was performed in 9 patients (21.95%) (p < 0.05). There was a decrease in the severity of postoperative pain in group 1, (3.4 В± 1.25 points on the visual analog scale), which was significantly lower than in group 2 (5.1 В± 3.4 points).Conclusions. Body weight reduction against the background of the use of GnRH agonists (goserelin) and inositols (Inofolic combi) due to the improvement of the technical conditions of the operation, metabolic and hematological indicators allow to reduce the duration of surgical intervention and the frequency of laparotomies in patients with uterine fibroids against the background of obesity and metabolic syndrome.

show abstract

Efficacy of myo‐inositol and d‐chiro‐inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open‐label study

Cited by 8 publications

References 23 publications

Management of polycystic ovary syndrome among Indian women using myo‐inositol and D-chiro-inositol

Management of polycystic ovary syndrome among Indian women using myo‐inositol and D-chiro-inositol

Dietary Management in Polycystic Ovary Syndrome: Review

Optimization of surgical treatment of uterine myoma in women with obesity and the metabolic syndrome

Contact Info

Product

Resources

About